Synthorx Inc (NASDAQ:THOR) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus target price of $26.67 for the company and are anticipating that the company will post ($0.38) EPS for the current quarter, according to Zacks. Zacks has also assigned Synthorx an industry rank of 74 out of 256 based on the ratings given to related companies.
Several analysts recently weighed in on the company. Zacks Investment Research downgraded Synthorx from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. Svb Leerink reiterated an “outperform” rating on shares of Synthorx in a research report on Monday, March 18th. Leerink Swann assumed coverage on Synthorx in a research report on Friday, March 15th. They issued an “outperform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Synthorx in a research report on Wednesday, May 1st.
NASDAQ:THOR traded up $0.37 during mid-day trading on Tuesday, hitting $12.59. 1,387 shares of the company’s stock traded hands, compared to its average volume of 85,795. The firm’s 50 day moving average price is $14.56. Synthorx has a 12 month low of $11.00 and a 12 month high of $23.53. The company has a market capitalization of $392.75 million and a price-to-earnings ratio of -1.92.
Synthorx (NASDAQ:THOR) last announced its earnings results on Tuesday, April 30th. The medical instruments supplier reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). On average, sell-side analysts forecast that Synthorx will post -1.65 earnings per share for the current year.
Synthorx Company Profile
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Featured Article: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.